NCT02548624

Brief Summary

The primary objective of the study is to examine the effectiveness of the Zephyr BioPatch in measuring position changes of a non-patient subject in a lab setting and to examine the effectiveness of the Zephyr BioPatch in measuring position changes of hospitalized patients.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Nov 2016

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 1, 2015

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 14, 2015

Completed
1.1 years until next milestone

Study Start

First participant enrolled

November 1, 2016

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
Last Updated

April 6, 2017

Status Verified

April 1, 2017

Enrollment Period

3 months

First QC Date

September 1, 2015

Last Update Submit

April 4, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Body position

    Body position will be classified as facing right, facing left, facing down (prone), or facing up (supine).

    During a 2.5 hour lab observation

  • Body position

    Body position when lying horizontally will be classified as facing right, facing left, facing down (prone), or facing up (supine).

    During a 24 hospital observation

Secondary Outcomes (1)

  • Performance of the Zephyr BioPatch position output in hospitalized patients of varying body mass indexes (BMI)

    During a 24 hospital observation.

Interventions

The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available. The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station.

Also known as: ZephyrLIFE Hospital System

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The laboratory observation will consist of one non-patient subject (N=1). The hospital observation will consist of 18 patients (N=18) hospitalized at the Columbia University Medical Center on the general care floor at-risk for hospital-acquired pressure ulcers. The hospitalized subjects will be stratified into three groups. Six subjects with normal BMI classification (18.5 -24.9), six with overweight BMI classification (25.0-29.9), and six with overweight BMI classification (30.0-39.9) will comprise the study sample.

You may qualify if:

  • Signed and dated informed consent by subject
  • Male or female of any race
  • At least 18 years of age
  • Willingness to have study device attached during study participation
  • Willingness to participate in all aspects of the study

You may not qualify if:

  • Implanted pacemaker or defibrillator
  • Allergy or sensitivity to ECG leads or similar types of adhesive
  • History of hospital admission or a surgical procedure in the 60 days prior to study enrollment
  • BMI \> 30.0
  • Signed and dated informed consent by subject
  • Male or female of any race
  • At least 18 years of age
  • Expected hospitalized admission on the general care floor for at least three days
  • At risk for hospital-acquired pressure ulcers as defined by score on the Braden Scale of \< 18
  • Willingness to have study devices attached during study participation
  • Willingness to participate in all aspects of the study
  • Implanted pacemaker or defibrillator
  • Allergy or sensitivity to ECG leads or similar types of adhesive
  • Subject will be sleeping in a chair or spending the majority of time in a chair
  • BMI \> 39.9

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University Medical Center

New York, New York, 10032, United States

Location

MeSH Terms

Conditions

Pressure Ulcer

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Jason Adelman, MD, MS

    Columbia University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2015

First Posted

September 14, 2015

Study Start

November 1, 2016

Primary Completion

February 1, 2017

Study Completion

February 1, 2017

Last Updated

April 6, 2017

Record last verified: 2017-04

Locations